Isotechnika to update investment community at Biofinance business forum



    EDMONTON, April 23 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today
that Dr. Randall Yatscoff, Isotechnika's President & CEO, will present a
corporate update at BioFinance to be held at the Marriot Eaton Centre Hotel in
Toronto, Ontario on Wednesday, April 25, 2007 at 9:30 a.m. EDT in the Trinity
Room IV.
    Interested parties will be able to access the presentation through the
Company's corporate web site at www.isotechnika.com in the Investor Relations
section. The corporate update can be viewed simultaneously with Dr. Yatscoff's
scheduled presentation on Wednesday, April 25.

    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Isotechnika
looks to become the leader in development of immunosuppressant therapies.
    Isotechnika's lead drug, ISA247, has successfully completed a Phase 3
Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is
currently being investigated in a combined Phase 3 European/Canadian psoriasis
trial and a Phase 2b North American trial for the prevention of kidney graft
rejection. One of our partners, Lux Biosciences, has received permission from
the Food and Drug Administration to investigate ISA247 in three separate
pivotal Phase 2/Phase 3 trials for the treatment of non-infectious uveitis and
as a maintenance therapy in uveitis. The Company also successfully completed
Phase 1 clinical trials of an additional immunosuppressive compound in its
drug pipeline, TAFA93.

    Forward-Looking Statements
    --------------------------
    This press release may contain forward-looking statements.
Forward-looking statements, including the Company's belief as to the potential
of its products, the Company's expectations regarding the issuance of
additional patents and the Company's ability to protect its intellectual
property, involve known and unknown risks and uncertainties, which could cause
the Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue research and
development projects, the ability to economically manufacture its products,
the potential of its products, the success and timely completion of clinical
studies and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from infringement
by third parties, and the risk that the Company's patents may be subsequently
shown to be invalid or infringe the patents of others. Investors should
consult the Company's quarterly and annual filings with the Canadian
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., (780) 487-1600 (247), (780) 484-4105 (fax),
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., (780) 487-1600 (243), 780-484-4105 (fax),
sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890